International Biotechnology Trust (LSE:IBT) Debt-to-EBITDA : (As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:IBT International Biotechnology Trust PLC LSE:IBT
43 GF Score
Price £11.10
GF Value £28.13
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is International Biotechnology Trust Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

International Biotechnology Trust's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2026 was £29.75 Mil. International Biotechnology Trust's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2026 was £0.00 Mil. International Biotechnology Trust's annualized EBITDA for the quarter that ended in Feb. 2026 was £171.82 Mil. International Biotechnology Trust's annualized Debt-to-EBITDA for the quarter that ended in Feb. 2026 was 0.17.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for International Biotechnology Trust's Debt-to-EBITDA or its related term are showing as below:

LSE:IBT's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.215
* Ranked among companies with meaningful Debt-to-EBITDA only.

International Biotechnology Trust  (LSE:IBT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

International Biotechnology Trust Debt-to-EBITDA Related Terms

International Biotechnology Trust Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for International Biotechnology Trust's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

International Biotechnology Trust Debt-to-EBITDA Chart

International Biotechnology Trust Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

International Biotechnology Trust Semi-Annual Data
Aug16 Feb17 Aug17 Feb18 Aug18 Feb19 Aug19 Feb20 Aug20 Feb21 Aug21 Feb22 Aug22 Feb23 Aug23 Feb24 Aug24 Feb25 Aug25 Feb26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

LSE:IBT vs VRTX, REGN, MRNA: Debt-to-EBITDA Comparison

For the Biotechnology subindustry, International Biotechnology Trust's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

International Biotechnology Trust Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, International Biotechnology Trust's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where International Biotechnology Trust's Debt-to-EBITDA falls into.


LSE:IBT
43GF Score
International Biotechnology Trust PLC LSE:IBT
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

International Biotechnology Trust Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

International Biotechnology Trust's Debt-to-EBITDA for the fiscal year that ended in Aug. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(29.607 + 0) / 0.798
=37.10

International Biotechnology Trust's annualized Debt-to-EBITDA for the quarter that ended in Feb. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(29.752 + 0) / 171.818
=0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Feb. 2026) EBITDA data.

Is International Biotechnology Trust (LSE:IBT) Overvalued in 2026?

Based on GuruFocus' analysis, International Biotechnology Trust stock appears to be undervalued. The current stock price of £11.10 is trading 60.5% below its estimated GF Value™ of £28.13. GuruFocus considers International Biotechnology Trust to be Significantly Undervalued.

Key valuation signals for LSE:IBT:

  • Debt-to-EBITDA:
  • GF Value™: £28.13 vs. price of £11.10 (60.5% below fair value)
  • GF Score™: 43/100 with 4 warning signs

No single metric tells the full story. See the LSE:IBT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

International Biotechnology Trust Business Description

Address 1 London Wall Place, London, GBR, EC2Y 5AU
International Biotechnology Trust PLC is an investment trust company. It aims at achieving long-term capital growth by investing in biotechnology and other life sciences companies. It seeks to achieve its objective by investing in a diversified portfolio of companies which has good growth prospects. It focuses on investments in biotechnology companies which are engaged in on drug discovery and development, medical devices companies and healthcare services provider. The invests in various financial instruments such as equities, index-linked securities, debt securities, cash deposits, money market instruments ,and foreign currency exchange transactions. Its revenue comprises of dividend, interest and other income from investment made.
43GF Score

Get the complete analysis for LSE:IBT

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£11.10
Price
£28.13
GF Value